QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast episode where CEO Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte(TM) for cutaneous T-cell lymphoma, noting strong blinded aggregate response rates above initial assumptions and outlining potential outcomes including early study completion or continued enrollment, while emphasizing upcoming interim and top-line data as potentially transformational milestones supporting commercialization and partnership opportunities. To view the full press release, visit https://ibn.fm/ETv8p About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.…